Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties

Critical Reviews in Toxicology

Volumn 46, Issue 7, 2016, Pages 587-614

  van der Laan, Jan Willem ^a   Kasper, Peter ^b   Silva Lima, Beatriz ^c   Jones, David R ^d   Pasanen, Markku ^e  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b Federal Institute for Drugs and Medical Devices BfArM   (Germany)

^c RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Carcinogenicity; human pharmaceuticals; NEGCARC paradigm; pharmacology; regulatory assessment

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALDOSE REDUCTASE INHIBITOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUSCARINIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE V INHIBITOR; PROTON PUMP INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRIPLE REUPTAKE INHIBITOR; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VASOPRESSIN ANTAGONIST; VITAMIN D DERIVATIVE; CARCINOGEN; DRUG;

CARCINOGENICITY; CHRONIC TOXICITY; DRUG EXPOSURE; HISTOPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; ANIMAL; CARCINOGEN TESTING; HUMAN; PHARMACOLOGY; RAT;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGICAL PHENOMENA; RATS;

EID: 84979307884     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2016.1163664     Document Type: Review

References (120)

1. S.C.Abraham, B.Nobukawa, F.M.Giardiello, S.R.Hamilton, T.T.Wu 2001. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 158:1005–1010.
2. R.H.Alison, C.C.Capen, D.E.Prentice 1994. Neoplastic lesions of questionable significance to humans. Toxicol Pathol. 22:179–186.
3. R.Ataee, S.Ajdary, M.Rezayat, M.A.Shokrgozar, S.Shahriari, M.R.Zarrindast 2010. Study of 5HT3 and HT4 receptor expression in HT29 cell line and human colon adenocarcinoma tissues. Arch Iran Med. 13:120–125.
4. L.Azoulay, H.Yin, C.Renoux, S.Suissa 2011. The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat. 129:541–548.
5. A.B.Beiderbeck-Noll, M.C.Sturkenboom, P.D.van der Linden, R.M.Herings, A.Hofman, J.W.Coebergh, H.G.Leufkens, B.H.Stricker. 2003. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer. 39:98–105.
6. G.J.Bergman, S.Khan, B.Danielsson, N.Borg 2014. Breast cancer risk and use of calcium channel blockers using Swedish population registries. JAMA Intern Med. 174:1700–1701.
7. G.Brambilla, A.Martelli 2009. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat Res. 681:209–229.
8. G.Brambilla, F.Mattioli, L.Robbiano, A.Martelli 2011. Genotoxicity and carcinogenicity studies of antihistamines. Arch Toxicol. 85:1173–1187.
9. D.J.Brees, M.R.Elwell, F.D.Tingley3rd, S.B.Sands, A.B.Jakowski, A.C.Shen, J.H.Cai, M.B.Finkelstein 2008. Pharmacological effects of nicotine on norepinephrine metabolism in rat brown adipose tissue: relevance to nicotinic therapies for smoking cessation. Toxicol Pathol. 36:568–575.
10. D.A.Brott, H.A.S.Andersson, J.Stewart, L.Ewart, G.Christoph, J.Harleman, D.Armstrong, L.B.Kinter. 2014. A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: mode of action consistent with dopamine agonism. Toxicol Rep. 1:1202–1212.
11. D.A.Brott, J.L.Werkheiser, P.Campbell, P.Bentley, H.H.Andersson, J.Stewart, R.Huby, M.Altekar, L.Kinter 2012. Inhibition of oestradiol-induced prolactin release in a dual-cannulated ovariectomized rat model by carmoxirole, a peripherally restricted dopamine agonist. Basic Clin Pharmacol Toxicol. 111:411–416.
12. J.E.Bueld, G.Bannenberg, K.J.Netter 1996. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat. Pharmacol Toxicol. 78:229–234.
13. P.J.Bugelski, A.Volk, M.R.Walker, J.H.Krayer, P.Martin, J.Descotes 2010. Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol. 29:435–466.
14. J.D.Burek, D.H.Patrick, R.J.Gerson 1998. Weight of biological evidence for assessing carcinogenicity. In: H.C.Grice, J.L.Cimina, editors. Carcinogenicity. New York: Springer-Verlag. p. 83–95.
15. G.Cabello, M.Valenzuela, A.Vilaxa, V.Durán, I.Rudolph, N.Hrepic, G.Calaf. 2001. A rat mammary tumor model induced by the organophosphorous pesticides parathion and malathion, possibly through acetylcholinesterase inhibition. Environ Health Perspect. 109:471–479.
16. C.C.Capen 2004. Mechanisms of hormone-mediated carcinogenesis of the ovary. Toxicol Pathol. 32:1–5.
17. H.W.Chang, C.Y.Huang, S.Y.Yang, V.C.Wu, T.S.Chu, Y.M.Chen, B.S.Hsieh, K.D.Wu 2014. Role of D2 dopamine receptor in adrenal cortical cell proliferation and aldosterone-producing adenoma tumorigenesis. J Mol Endocrinol. 52:87–96.
18. K.Cheng, R.Samimi, G.Xie, J.Shant, C.Drachenberg, M.Wade, R.J.Davis, G.Nomikos, J.P.Raufman 2008. Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol. 295:G591–G597.
19. S.M.Cohen 2004. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol Sci. 80:225–229.
20. S.M.Cohen 2010. An enhanced 13-week bioassay: an alternative to the 2-year bioassay to screen for human carcinogenesis. Exp Toxicol Pathol. 62:497–502.
21. J.F.Contrera, A.C.Jacobs, J.J.DeGeorge 1997. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul Toxicol Pharmacol. 25:130–145.
22. J.C.Cook, G.R.Klinefelter, J.F.Hardisty, R.M.Sharpe, P.M.D.Foster 1999. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms and relevance to humans. Crit Rev Toxicol. 29:169–261.
23. M.Dempster, C.L.E.Siezen, S.J.Ter Braak, W.J.van den Brink, A.Emerenciana, F.Bellanti, R.G.Duijnhoven, M.S.A.Kwa, J.W.Van der Laan. 2015. Carcinogenicity of biopharmaceuticals. In: M.Graziano, D.Jacobson Kram, editors. Genotoxicity and carcinogenicity testing of pharmaceuticals. Berlin: Springer. p. 125–157.
24. L.Dethloff, B.Barr, L.Bestervelt, S.Bulera, R.Sigler, M.LaGattuta, F.de La Iglesia 2000. Gabapentin-induced mitogenic activity in rat pancreatic acinar cells. Toxicol Sci. 55:52–59.
25. E.J.de Waal, M.Desmidt, S.Korte, M.Niehoff, K.Chase, W.Arrowsmith, A.Lampo 2014. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics. J Appl Toxicol. 34:974–992.
26. G.Dirami, K.J.Teerds, B.A.Cooke 1996. Effect of a dopamine agonist on the development of Leydig cell hyperplasia in Sprague-Dawley rats. Toxicol Appl Pharmacol. 141:169–177.
27. G.Dockray, R.Dimaline, A.Varro 2005. Gastrin: old hormone, new functions. Pflugers Arch. 449:344–355.
28. M.A.Dominick, M.R.White, T.P.Sanderson, T.Van Vleet, S.M.Cohen, L.E.Arnold, M.Cano, S.Tannehill-Gregg, J.D.Moehlenkamp, C.R.Waites, et al. 2006. Urothelial carcinogenesis in the urinary bladder of male rats with Muraglitazar, a PPARa/g agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol. 34:903–920.
29. B.R.Douglas, R.A.Woutersen, J.B.Jansen, A.J.de Jong, L.C.Rovati, C.B.Lamers 1989. Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin onazaserine-induced lesions in rat pancreas. Gastroenterology. 96:462–469.
30. EMA. 2006. CHMP SWP Reflection Paper on PPARs (Peroxisome Proliferator Activated Receptors)
31. EMA. 2012. EPAR Pioglitazone. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000285/WC500126656.pdf
32. F.L.Egerod, H.S.Nielsen, L.Iversen, I.Thorup, T.Storgaard, M.B.Oleksiewicz 2005. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 10:295–309.
33. H.Frucht, R.T.Jensen, D.Dexter, W.L.Yang, Y.Xiao 1999. Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clin Cancer Res. 5:2532–2539.
34. A.Friedrich, K.Olejniczak 2011. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995–2009). Regul Toxicol Pharmacol. 60:225–248.
35. A.Funakoshi, K.Tateishi, M.Tsuru, A.Jimi, H.Wakasugi, A.Kono 1991. Acetylcholine regulates pancreastatin secretion from the human pancreastatin-producing cell line (QGP-1N). J Clin Endocrinol Metab. 73:151–155.
36. J.J.Gildea, X.Wang, N.Shah, H.Tran, M.Spinosa, R.Van Sciver, M.Sasaki, J.Yatabe, R.M.Carey, P.A.Jose, R.A.Felder 2012. Dopamine and angiotensin type 2 receptors cooperatively inhibit sodium transport in human renal proximal tubule cells. Hypertension. 60:396–403.
37. L.S.Gold, T.H.Slone, B.R.Stern, L.Bernstein. 1993. Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals. Mutat Res. 286:75–100.
38. M.Göoz, P.Göoz, L.M.Luttrell, J.R.Raymond. 2006. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumour necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem. 281:21004–21012.
39. C.Gopinath 1987a. The urinary system. In: C.Gopinath, D.E.Prentice, D.J.Lewis, editors. Atlas of experimental toxicological pathology. Lancaster, Boston, The Hague, Dordrecht: MTP Press Limited. p. 77–90 (Chapter 5).
40. C.Gopinath 1987b. The reproductive system. In: C.Gopinath, D.E.Prentice, D.J.Lewis, editors. Atlas of experimental toxicological pathology. Lancaster, Boston, The Hague, Dordrecht: MTP Press Limited. p. 91–103 (Chapter 6).
41. C.Gopinath 1987c. The endocrine glands. In: C.Gopinath, D.E.Prentice, D.J.Lewis, editors. Atlas of experimental toxicological pathology. Lancaster, Boston, The Hague, Dordrecht: MTP Press Limited. p. 104–121 (Chapter 7).
42. C.Gopinath, W.A.Gibson 1987. Mesovarian Leiomyomas in the rat. Environ Health Perspect. 73:107–113.
43. E.Gottman, S.Kramer, B.Pfahringer, C.Helma 2001. Data quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments. Environ Health Perspect. 109:509–514.
44. O.M.Granata, L.Cocciadifero, I.Campisi, V.Miceli, G.Montalto, L.M.Polito, B.Agostara, G.Carruba 2009. Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells. J Steroid Biochem Mol Biol. 113:290–295.
45. L.Grimaldi-Bensouda, O.Klungel, X.Kurz, M.C.de Groot, A.S.Maciel Afonso, M.L.de Bruin, R.Reynolds, M.Rossignol. 2016. Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open. 6:e009147. doi: 10.1136/bmjopen-2015-009147.
46. G.C.Hard, M.J.Iatropoulos, K.Jordan, L.Radi, O.P.Kaltenberg, A.R.Imondi, G.M.Williams 1993. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53:4534–4541.
47. B.Harrison 2007. Endocrine surgical aspects of multiple endocrine neoplasia syndromes in children. Horm Res. 68:105–106.
48. P.W.Harvey 2012. Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific. J Appl Toxicol. 32:1–9.
49. S.Hata, Y.Miki, R.Saito, K.Ishida, M.Watanabe, H.Sasano. 2013. Aromatase in human liver and its diseases. Cancer Med. 2:305–315.
50. L.G.Hernández, H.van Steeg, M.Luijten, J.van Benthem. 2009. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutat Res. 682:94–109. doi: 10.1016/j.mrrev.2009.07.002
51. S.R.Hügl, M.Merger 2007. Prolactin stimulates proliferation of the glucose-dependent beta-cell line INS-1 via different IRS-proteins. JOP (Online) 8:739–752.
52. H.J.Hugo, C.Saunders, R.G.Ramsay, E.W.Thompson. 2015. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia. 20:109–119.
53. International Agency for Research on Cancer. 1996. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 66, Final draft Decision on Chemical agents and related occupations.
54. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2012. IARC Monogr Eval Carcinog Risks Hum. 100:9–562. Review. Pharmaceutical drugs. IARC, Lyon.
55. ICH 2011 S6R1. Preclinical safety evaluation of biotechnology-derived pharmaceuticals; [cited 2015 Dec 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002828.pdf,
56. ICH 2016 S1. Regulatory Notice Document; [cited 2016 Jan 23 ]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S1/S1_RND_Revisions_22
57. S.Ikezaki, A.Nishikawa, F.Furukawa, Z.Tanakamaru, H.Nakamura, H.Mori, M.Hirose 1999. Influences of long-term administration of 24R, 25-dihydroxyvitamin D3, a vitamin D3 derivative, in rats. J Toxicol Sci. 24:133–139.
58. H.Ishiguro, T.Kawahara, Y.Zheng, E.Kashiwagi, Y.Li, H.Miyamoto. 2014. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemother Pharmacol. 74:249–255.
59. A.Jacobs 2005. Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing? Toxicol Sci. 88:18–23.
60. D.Jack, D.Poynter, N.W.Spurling 1983. Beta-adrenoceptor stimulants and mesovarian leiomyomas in the rat. Toxicology. 27:315–320.
61. D.Julius, T.J.Livelli, T.M.Jessell, R.Axel. 1989. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science. 244:1057–1062.
62. S.Karlsson, Y.Hirsimäki, E.Mäntylä, L.Nieminen, L.Kangas, P.Hirsimäki, C.J.Perry, M.Mulhern, P.Millar, J.Handa, G.M.Williams. 1996. A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem Toxicol. 19:245–266.
63. M.J.Keiser, V.Setola, J.J.Irwin, C.Laggner, A.I.Abbas, S.J.Hufeisen, N.H.Jensen, M.B.Kuijer, R.C.Matos, T.B.Tran,. 2009. Predicting new molecular targets for known drugs. Nature. 462:175–181.
64. Y.Kiriyama, H.Tsuchiya, T.Murakami, K.Satoh, Y.Tokumitsu. 2001. Calcitonin induces IL-6 production via both PKA and PKC pathways in the pituitary folliculo-stellate cell line. Endocrinology. 142:3563–3569.
65. M.W.Kloss, D.H.Patrick, J.S.MacDonald 1991. Studies on the effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the rodent forestomach. Food Chem Toxicol. 29:621–628.
66. L.B.Knudsen 2010. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl. 2010:4–11. doi: 10.1111/j.1742-1241.2010.02499.x.
67. K.J.LePard, J.R.Mohammed, R.L.StephensJr.1997. Gastric ECL-cell hyperplasia produces enhanced basal and stimulated gastric acid output but not gastric erosion formation in the rat. Gen Pharmacol. 28:415–420.
68. D.Levin, S.Bell, R.Sund, S.A.Hartikainen, J.Tuomilehto, E.Pukkala, I.Keskimäki, E.Badrick, A.G.Renehan, I.E.Buchan,. 2015. Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 58:493–504.
69. J.D.Lewis, L.A.Habel, C.P.Quesenberry, B.L.Strom, T.Peng, M.M.Hedderson, S.F.Ehrlich, R.Mamtani, W.Bilker, D.J.Vaughn,. 2015. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 314:265–277.
70. C.I.Li, J.R.Daling, M.T.Tang, K.L.Haugen, P.L.Porter, K.E.Malone. 2013. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med. 173:1629–1637.
71. X.Li, S.S.Pathi, S.Safe 2015. Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors. BMC Cancer. 15:974.
72. H.Liang, P.Kowalczyk, J.J.Junco, H.L.Klug-De Santiago, G.Malik, S.J.Wei, T.J.Slaga. 2014. Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors. Mol Carcinog. 53:753–763.
73. H.Luksch, O.Uckermann, A.Stepulak, S.Hendruschk, J.Marzahn, S.Bastian, C.Staufner, A.Temme, C.Ikonomidou. 2011. Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res. 31:3181–3192.
74. E.A.Martin, K.Brown, M.Gaskell, F.Al-Azzawi, R.C.Garner, D.J.Boocock, E.Mattock, D.W.Pring, K.Dingley, K.W.Turteltaub,. 2003. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63:8461–8465.
75. R.M.McClain 1989. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol Pathol. 17:294–306.
76. J.W.Newberne, P.M.Newberne, J.P.Gibson, K.W.Huffman, F.P.Palopoli. 1977. Lack of carcinogenicity of oxprenolol, a beta-adrenergic blocking agent. Toxicol Appl Pharmacol. 41:535–546.
77. R.Ogawa, M.B.Streiff, A.Bugayenko, G.J.Kato. 2002. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood. 99:3390–3397.
78. M.B.Oleksiewicz, I.Thorup, H.S.Nielsen, H.V.Andersen, A.C.Hegelund, L.Iversen, T.S.Guldberg, P.R.Brinck, I.Sjogren, U.K.Thinggaard,. 2005. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol. 33:552–560.
79. L.Pacini, E.De Falco, M.Di Bari, A.Coccia, C.Siciliano, D.Ponti, A.L.Pastore, V.Petrozza, A.Carbone, A.M.Tata, et al. 2014. M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells. Cancer Biol Ther. 15:1489–1498.
80. M.Pahor, C.D.Furberg 1998. Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. Drugs Aging. 13:99–108.
81. S.Park, J.M.Han, J.Cheon, J.I.Hwang, J.Y.Seong. 2014. Apoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist. PLoS One. 9:e99723.
82. N.Pathomthongtaweechai, S.Soodvilai, V.Chatsudthipong, C.Muanprasat. 2014. Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase. Eur J Pharmacol. 724:67–76.
83. M.Princivalle, P.Broqua, R.White, J.Meyer, G.Mayer, L.Elliott, K.Bjarnason, R.Haigh, C.Yea. 2007. Rapid suppression of plasma testosterone levels andtumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther. 320:1113–1118.
84. M.A.Pufall 2015. Glucocorticoids and cancer. Adv Exp Med Biol. 872:315–333.
85. Z.Radi, P.Bartholomew, M.Elwell, W.M.Vogel. 2013. Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma. Toxicol Appl Pharmacol. 273:456–463.
86. N.M.Rajamannan, N.Caplice, F.Anthikad, T.J.Sebo, T.A.Orszulak, W.D.Edwards, J.Tajik, R.S.Schwartz. 2001. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis. 10:827–831.
87. A.G.Rauws, E.J.De Waal, J.W.Van der Laan 1997. Sense and non-sense in toxicity assessment of medicinal products. Adv Drug Res. 30:15–72.
88. M.V.Reddy, F.D.Sistare, J.S.Christensen, J.G.DeLuca, G.K.Wollenberg, J.J.DeGeorge. 2010. An evaluation of chronic 6-and 12-month rat toxicology studies as predictors of 2-year tumor outcome. Vet Pathol. 47:614–629.
89. G.A.Reif, T.Yamaguchi, E.Nivens, H.Fujiki, C.S.Pinto, D.P.Wallace. 2011. Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 301:F1005–F1013.
90. L.E.Rimmaudo, E.de la Torre, E.Sacerdote de Lustig, M.E.Sales 2005. Muscarinic receptors are involved in LMM3tumor cells proliferation and angiogenesis. Biochem Biophys Res Commun. 334:1359–1364.
91. R.L.Robison, W.Suter, R.H.Cox 1994. Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor. Fundam Appl Toxicol. 23:9–20.
92. F.J.C.Roe, A.Bar 1985. Enzootic and epizootic adrenal medullary proliferative disease of rats; influence of dietary factors which affect calcium absorption. Hum Toxicol. 4:27–52.
93. M.A.Rogawski, C.W.Bazil 2008. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 8:345–352.
94. B.Rubí, S.Ljubicic, S.Pournourmohammadi, S.Carobbio, M.Armanet, C.Bartley, P.Maechler. 2005. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem. 280:36824–36832.
95. S.Savari, M.Liu, Y.Zhang, W.Sime, A.Sjölander 2013. CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS One. 8:e73466. doi: 10.1371/journal.pone.0073466. eCollection 2013.
96. R.E.Sigler, A.W.Gough, F.A.DelaIglesia 1995. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology. 98:73–82.
97. B.M.Silva Lima, J.W.Van der Laan 2000. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol. 32:135–143.
98. F.D.Sistare, D.Morton, C.Alden, J.Christensen, D.Keller, S.D.Jonghe, R.D.Storer, M.V.Reddy, A.Kraynak, B.Trela,. 2011. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol Pathol. 39:716–744.
99. R.D.Snyder, J.W.Green 2001. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res. 488:151–169.
100. M.Sponziello, A.Verrienti, F.Rosignolo, R.F.De Rose, V.Pecce, V.Maggisano, C.Durante, S.Bulotta, G.Damante, L.Giacomelli,. 2015. PDE5 expression in human thyroidtumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine. 50:434–441.
101. G.Stefansdottir, S.Zoungas, J.Chalmers, M.J.Knol, H.G.Leufkens, M.Woodward, A.Patel, D.E.Grobbee, M.L.De Bruin. 2013. The post hoc use of randomised controlled trials to explore drug associated cancer outcomes: methodological challenges. Curr Drug Saf. 8:371–378.
102. M.Syed, C.Fenoglio-Preiser, K.A.Skau, G.F.Weber. 2008. Acetylcholinesterase supports anchorage independence in colon cancer. Clin Exp Metastasis. 25:787–798.
103. R.Tammali, A.B.Reddy, K.V.Ramana, J.M.Petrash, S.K.Srivastava. 2009. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis. 30:799–807.
104. R.Tammali, A.B.Reddy, A.Saxena, P.G.Rychahou, B.M.Evers, S.Qiu, S.Awasthi, K.V.Ramana, S.K.Srivastava. 2011. Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis. 32:1259–1267.
105. B.Ter Braak, C.L.Siezen, N.Kannegieter, E.Koedoot, B.van de Water, J.W.van der Laan. 2014. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. Arch. Toxicol. 88:953–966
106. A.S.Tischler, R.A.DeLellis 1988. The rat adrenal medulla. II Proliferative lesions. J Am Coll Toxicol. 7:23–44.
107. A.S.Tischler, R.A.DeLellis, G.Nunnemacher, H.J.Wolfe. 1988. Acute stimulation of chromaffin cell proliferation in the adult rat adrenal medulla. Lab Invest. 58:733–735.
108. A.S.Tischler, J.F.Powers, M.Pignatello, P.Tsokas, J.C.Downing, R.M.McClain. 1999. Vitamin D3-induced proliferative lesions in the rat adrenal medulla. Toxicol Sci. 51:9–18.
109. T.H.Tsai, R.E.Beitman, J.P.Gibson, E.J.Larson, H.Friehe, R.Fontaine. 1982. Acute, subacute and chronic toxicity/Carcinogenicity of lofexidine. Arzneimittelforschung. 32:955–962.
110. M.Tsuchioka, M.Takebayashi, K.Hisaoka, N.Maeda, Y.Nakata. 2008. Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells. J Neurochem. 106:244–257. [Epub 2008 Jul 1].
111. S.S.Tworoger, A.H.Eliassen, P.Sluss, S.E.Hankinson. 2007. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 25:1482–1488.
112. H.Van Cauteren, K.Van Deun, P.Vanparijs, W.Coussement, Vandenbrughe. 1992. The penfluridol case. In: McAuslane, C.E.Lumley, S.R.Walker, editors. The carcinogenicity debate. CMR Workshop Series. Lancaster, England: Quay Publ. p. 247–254.
113. J.S.Vaidya, G.Baldassarre, M.A.Thorat, S.Massarut. 2010. Role of glucocorticoids in breast cancer. Curr Pharm Des. 16:3593–3600.
114. J.P.J.Van Oosterhout, J.W.Van der Laan, E.J.De Waal, K.Olejniczak, M.Hilgenfeld, V.Schmidt, R.Bass. 1997. The utility of two Rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol. 25:6–17.
115. C.L.Varley, J.Southgate 2008. Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol. 60:435–441.
116. P.S.Wang, A.M.Walker, M.T.Tsuang 2002. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 59:1147–1154.
117. G.M.Williams, M.J.Iatropoulos, S.Karlsson 1997. Initiating activity of the anti-estrogen tamoxifen, but not toremifene in rat liver. Carcinogenesis. 18:2247–2253.
118. D.J.Wright, J.N.Earnhardt, R.Perry, S.Bailey, B.Komm, D.R.Minck, M.A.Cukierski. 2013. Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene. J Cell Physiol. 228:724–733.
119. F.Yamaguchi, Y.Hirata, H.Akram, K.Kamitori, Y.Dong, L.Sui, M.Tokuda. 2013. FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer. 13:468–478.
120. M.Yamamoto, A.Markatos, J.G.Seedor, P.Masarachia, M.Gentile, G.A.Rodan, R.Balena. 1993. The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats. Calcif Tissue Int. 53:278–282.